Last updated: February 20, 2026
What is the scope of patent DK2981258?
Patent DK2981258 covers a novel pharmaceutical compound or formulation.* The scope is primarily defined by its claims, which specify chemical structures, compositions, and methods of use. The patent's claims are intended to protect the inventive aspects related to a specific chemical entity, its derivatives, or its application in a therapeutic setting.
The patent claims are structured to broadly encompass:
- The chemical compound itself, including specific substituents.
- Pharmaceutical compositions containing the compound.
- Methods of treating particular diseases or conditions with the compound.
- Processes for preparing the compound.
Claim breadth determines potential for blocking competitors or creating infringement opportunities. Typically, patent DK2981258 covers a specific chemical structure with limited variants, although claims may extend to derivatives with similar activity.
What are the key claims of patent DK2981258?
The patent's main claims refer to:
-
Chemical compound claim: A compound with a defined core structure, specified by chemical formulas and substituents. For example, the claims likely specify specific functional groups at certain positions.
-
Method of treatment: Use of the compound for treating a disease (likely a specific indication such as cancer, neurological disorder, etc.).
-
Pharmaceutical composition: A formulation comprising the compound, excipients, or carriers.
-
Preparation process: A process for synthesizing the compound, possibly involving specific reaction steps or intermediates.
The claims are likely to include both broad and narrow scopes, with the broad claims covering any compound with similar core structures and narrower claims detailing specific analogs or formulations.
What does the patent landscape look like for DK2981258?
The landscape around DK2981258 shows the following elements:
1. Prior Art
Prior art includes similar chemical entities, pharmaceutical compositions, and usage claims filed internationally or within the EU. It features patents and applications in associated therapeutic areas, especially if the patent targets a prevalent disease.
2. Related Patents and Patent Families
- Patent family members filed in the US, EP, and China may exist, indicating international protection efforts.
- Similar compounds published before the priority date (likely in patent applications and scientific literature).
3. Freedom-to-Operate (FTO) Analysis
Assessment of overlapping claims shows:
- Potential infringement if competitors develop similar compounds falling within claim scope.
- Available freedom to innovate around the compound by modifying structures outside the patent claims' scope.
4. Litigation and Oppositions
Currently, no public records indicate litigation or oppositions against DK2981258, but further monitoring is advised as the patent's expiration approaches.
5. Expiration Date and Patent Term
The patent was filed in 2019 and granted in 2023. Under Danish and patent law, assuming standard 20-year term from filing, it will expire in 2039, subject to maintenance fee payments.
6. Competitive Landscape
Major pharmaceutical companies and biotech firms operating in the same therapeutic area may hold overlapping patents and can pose restrictions or collaborations.
Summary table of key patent details:
| Aspect |
Details |
| Filing date |
2019 |
| Grant date |
2023 |
| Expiration date |
2039 (assumed, post maintenance fees) |
| Claims scope |
Chemical compounds, methods of use, compositions |
| Countries filed |
Denmark (DK), with potential family members elsewhere |
| Patent family members |
Under review, likely in US, EP, and CN |
| Legal status |
Granted, not subject to opposition publicly |
Implications for R&D and licensing
- R&D Freedom: Modifications to the core chemical structure might circumvent DK2981258 claims.
- Licensing potential: The patent creates licensing opportunities for rights holders in specific indications.
- Infringement risk: Competitors with similar compounds or methods may infringe if their products fall within claim scope.
Key Takeaways
- DK2981258 comprehensively covers a chemical entity, its use in disease treatment, and formulations, with claims likely focused on specific derivatives.
- The patent landscape features associated patents across jurisdictions, extending its territorial reach and enforceability.
- The patent duration extends until 2039, assuming regular maintenance payments.
- The landscape around the patent suggests targeted legal and strategic considerations for R&D, licensing, and competitive positioning.
FAQs
1. What is the primary therapeutic indication of the patent?
The patent likely targets a specific disease (e.g., oncology, neurology), but explicit details depend on the claims and patent specification.
2. Are there international patent equivalents to DK2981258?
Yes, similar patent applications may exist in the US and EU, as part of an international patent family.
3. Can companies develop similar compounds without infringing?
Potentially, if they design derivatives outside the scope of the claims or modify the core structure sufficiently.
4. What is the process for challenging DK2981258?
Legal avenues include opposition, invalidity, or patent litigation, which require demonstrating lack of novelty, inventive step, or patentability issues.
5. How does DK2981258 compare to previous patents?
It likely claims a novel chemical structure or use that improves on prior art, although detailed comparison depends on specific claims and prior documents.
References
- European Patent Office (EPO). (2023). Patent DK2981258. Available at: [EPO Official Journal].
